MedPath

Individualized Fortification of Breast Milk

Not Applicable
Conditions
Postnatal Growth Disorder
Neurodevelopment
Registration Number
NCT01609894
Lead Sponsor
McMaster Children's Hospital
Brief Summary

The proposed research will investigate individualized fortification of breast milk based on daily milk analysis of carbohydrate, protein, and fat content in a randomized double blind controlled trial. The combination of additional fat, carbohydrate and protein and commercial fortifier will be added to ensure that the milk contains the target amounts of nutrient. Growth and development of these infants will be compared with that of infants fed mother's milk that has been supplemented with the current standard amounts. The postnatal growth of the infants will be assessed by measuring weight, length and head circumference and fat and lean mass using highly accurate, non-invasive methods throughout the intervention period and at the first follow-up visit after discharge at 3 months. Neurological development will be analyzed at the age of 18 months.

The investigators hypothesize that individualized fortification of breast milk improves the nutritional intake of preterm infants, optimizing growth, and thus this will positively impact neurodevelopment and health.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
112
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
growth during first three weeks of interventionfirst three weeks during intervention before 36 weeks of gestation

change in body weight gain will be accessed daily.

Secondary Outcome Measures
NameTimeMethod
weight gainfrom inclusion at postmentrual age <32 weeks until 18 month corrected age

change in body weight \[g\]

head circumferencefrom inclusion at postmentrual age <32 weeks until 18 month corrected age

change in head circumference \[cm\]

neurodevelopmentat 18 month corrected age

Bayley Scales of Infant Development III

body lengthfrom inclusion at postmentrual age <32 weeks until 18 month corrected age

change in body length \[cm\]

body compositionfrom inclusion at postmentrual age <32 weeks until 3 month corrected age

change in body composition measured with air displacement plethysmography (body weight, body volume, calculated fat and lean mass)

feeding intoleranceduring intervention (postmentrual age <32 weeks until 36 weeks)

occurence of feeding intolerance defined by vomitting, bloody gastric residuals, or abnormal abdomen (tender, discolored, absent bowel sounds)

nutrient's blood parameterduring intervention (postmentrual age <32 weeks until 36 weeks)

triglycerides, glucose, blood urea nitrogen, blood gases, electrolytes, pH

breast milk analysisduring intervention (postmentrual age <32 weeks until 36 weeks)

using near-infrared analysis breast milk's macronutrients (fat, lactose and protein) will be measured daily

enteral energy intakefrom inclusion at postmentrual age <32 weeks until 36 weeks

fat, carbohydrate, protein, and caloric intake by enteral feeding will be assesed daily

skin fold thicknessfrom inclusion at postmentrual age <32 weeks until 18 month corrected age

change in skin fold thickness \[cm\]

body composition (bio-electrical impedance analysis)from inclusion at postmentrual age <32 weeks until 18 month corrected age

change in body composition measured with bio-electrical impedance analysis (impedance at 5, 50, 100 and 200 kHz, resistance at 50 kHz, reactance at 50 kHz, phase angle at 50 kHz)

morbidityduring intervention (postmentrual age <32 weeks until 36 weeks)

Trial Locations

Locations (1)

Faculty of Health Science, McMaster Children's Hospital

🇨🇦

Hamilton, Ontario, Canada

Faculty of Health Science, McMaster Children's Hospital
🇨🇦Hamilton, Ontario, Canada
Christoph Fusch, MD, PhD, FRCPC
Principal Investigator
Niels Rochow, MD
Sub Investigator
Gerhard Fusch, PhD
Sub Investigator
Salhab el Helou, MD, FRCPC
Sub Investigator
Sabiha Ahmad
Sub Investigator
Akshdeep Singh Bhatia
Sub Investigator
Klaus Wutzke, PhD
Sub Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.